Dyno Therapeutics
Watertown, US · 9 known investors
Dyno Therapeutics develops artificial intelligence-powered genetic technologies for gene therapy, specifically engineering adeno-associated virus (AAV) capsids to improve gene delivery for treating genetic diseases. The company works with pharmaceutical partners including Novartis, Sarepta, Roche, Spark, and Astellas to advance therapies for patients with genetic disorders.
Founders & leadership
EK
Eric KelsicCEO & Cofounder
SS
Sam SinaiVice President, Head of ML & Cofounder
AV
Adrian VeresChief Scientific Officer & Cofounder
GC
George ChurchScientific Cofounder
TB
Tomas BjorklundScientific Co-founder
AC
Alan CraneExecutive Chairman & Cofounder, Polaris Entrepreneur Partner
Investors · 9
Andreessen HorowitzMenlo Park · $500K – $50M
CRV (Charles River Ventures)Bay Area · $250K – $5M
GENERAL INCEPTIONPalo Alto
GV (Google Ventures)Mountain View · $250K – $50M
Lux CapitalNew York · $100K – $100M
Obvious VenturesSan Francisco · $250K – $6M
Casdin CapitalreportedNew York
KdT Venturesreported · 2 sourcesAustin · $500K – $3M
Polaris PartnersreportedBoston · $500K – $5M
In the news
- Dyno raises $100 million to bring artificial intelligence to gene therapy - The Boston Globebostonglobe.com · 2021
- Dyno Therapeutics Raises $100 Million to Accelerate AI‑powered Gene Therapy Platform - Global Genesglobalgenes.org · 2021
- Dyno Therapeutics Emerges with AI Platform and Two Deals to Improve Delivery of Gene Therapies - Global Genesglobalgenes.org · 2020
- Dyno Therapeutics Raises $9M in Seed Financing - FinSMEsfinsmes.com · 2020